AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novel Coronavirus Treatment

1,137.434

+8.8310.78%

Number of Gainers:13

Number of Losers:6

Number of Flat:13

PE:- -

High:1,139.977

Open:1,135.959

Low:1,132.496

Close:1,128.603

Volume:45.85M

Turnover:241.84M

Market Cap:293.15B

Float Cap:233.35B

Loading ...

Solventum Announces Secondary Offering of 8.8 Million Shares by 3M

MT Newswires Live

The only 3 Australian stocks I'd hold forever

ASX Penny Stock Insights Featuring Duratec And 2 More

Simply Wall St.

BMW Invests Over €30 Million in New Custom Paint Center at Dingolfing Plant

How Investors May Respond To CSL (ASX:CSL) Gaining Canadian Approval for ANDEMBRY in Rare Disease Market

Simply Wall St.

Should you buy the rebound in CSL shares today?

How to build a $250,000 ASX share portfolio starting at zero

Beat the RBA cuts with these top ASX dividend stocks

Top Premarket Gainers

MT Newswires Live

Looking for big income? 2 ASX dividend stocks to buy today

BRIEF-Anteotech Executes Commission Agency Agreement With Kangshin Industrial Co

Anteotech Ltd-Appointment of South Korean Distributor

THOMSON REUTERS

Here's Why We're Watching Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Simply Wall St.

Dimerix's Potential US FDA Approval Can Add AU$119 Million in Development Milestone Payments, Says Euroz Hartleys

MT Newswires Live

Australian Regulator Proposes Granting Authorization to Establish Soft Plastic Recycling Scheme

MT Newswires Live

CSL Shares Rise Upon Receipt of Canada Marketing Approval

MT Newswires Live

Noxopharm Advances HERACLES Trial as Sofra Platform Gains US Momentum

Noxopharm Ltd-Heracles Clinical Trial Update 2

THOMSON REUTERS

2 ASX 200 shares that could make it rain dividends

Top brokers name 3 ASX shares to buy next week

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7501/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"Novel Coronavirus Treatment","latestPrice":1137.4335,"timestamp":1755143581251,"preClose":1128.6025,"halted":0,"volume":45853910,"delay":0,"changeRate":0.007825,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":8.830933,"latestTime":"08-14 13:53:01 AEST","open":1135.9585,"high":1139.9773,"low":1132.496,"amount":241836457,"amplitude":0.006629,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1755151200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1755129600000,1755151200000]],"turnoverRate":0.003201,"increases":13,"decrements":7,"flats":13,"marketCap":293153462110.25,"floatMarketCap":233346442219.64844},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":1139.9773,"amplitude":0.006629,"preClose":1128.6025,"low":1132.496,"latestPrice":1137.4335,"volume":45853910,"delay":0,"open":1135.9585,"prevYearClose":1117.913,"prevWeekClose":1101.875,"prevMonthClose":1126.988,"prevQuarterClose":1033.641,"fiveDayClose":1115.48,"twentyDayClose":1054.034,"sixtyDayClose":1056.93,"secType":"PLATE","market":"AU","turnoverRate":0.003201,"marketCap":293153462110.25,"floatMarketCap":233346442219.64844,"timestamp":1755143581251,"nameCN":"Novel Coronavirus Treatment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":13,"down":6,"flat":13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559849469","title":"Solventum Announces Secondary Offering of 8.8 Million Shares by 3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2559849469","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559849469?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:18","pubTimestamp":1755119914,"startTime":"0","endTime":"0","summary":"Solventum (SOLV) announced on Wednesday the launch of a secondary offering of 8.8 shares by selling shareholder 3M Company (MMM).Solventum will not get any proceeds from the offering, it said.Shares of the company were down over 1% in after hours trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","BK4533","BK4512","LU0683600562.USD","LU1093756325.SGD","BK4534","LU1894683348.USD","MMM.AU","SG9999002224.SGD","SG9999002232.USD","BK4588","BK7049","LU1894683264.USD","MMM","BK7501","LU0787776722.HKD","BK4198","BK7040","BK4206","BK4585","SOLV"],"gpt_icon":0},{"id":"2559989733","title":"The only 3 Australian stocks I'd hold forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2559989733","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559989733?lang=en_us&edition=fundamental","pubTime":"2025-08-14 03:23","pubTimestamp":1755112980,"startTime":"0","endTime":"0","summary":"Some companies are worth buying and never selling. They operate in industries with strong long-term demand, have durable competitive advantages, and can reinvest profits to keep growing year after yea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/14/the-only-3-australian-stocks-id-hold-forever/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","CSL.AU","BK7503","XJO.AU","RMD.AU","XAO.AU","BK7067","XKO.AU","BK7016","WTC.AU","BK7508","BK7007","BK7511"],"gpt_icon":0},{"id":"2559981046","title":"ASX Penny Stock Insights Featuring Duratec And 2 More","url":"https://stock-news.laohu8.com/highlight/detail?id=2559981046","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559981046?lang=en_us&edition=fundamental","pubTime":"2025-08-14 03:02","pubTimestamp":1755111730,"startTime":"0","endTime":"0","summary":"The Australian market has seen a mixed performance recently, with sectors like Health Care and Materials showing resilience despite broader challenges in Utilities and Financials. In such fluctuating conditions, identifying stocks with strong financial foundations becomes crucial for investors seeking stability and growth. Penny stocks, while sometimes perceived as outdated, can still offer valuable opportunities when backed by solid fundamentals; this article will explore three such...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-penny-stock-insights-featuring-duratec-and-2-more","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CLX.AU","BK7007","BK7055","GNG.AU","BK7501","BK7077","BK7129","BK7506","SPL.AU","BK7096","EZZ.AU","IGL.AU","BK7104","ANG.AU","WAF.AU","BK7062","GTN.AU","AAL.AU","RPL.AU","AHC.AU","BIS.AU","DUR.AU","BK7048","BK7058","BK7508","BK7045","BK7095"],"gpt_icon":0},{"id":"2559705836","title":"BMW Invests Over €30 Million in New Custom Paint Center at Dingolfing Plant","url":"https://stock-news.laohu8.com/highlight/detail?id=2559705836","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559705836?lang=en_us&edition=fundamental","pubTime":"2025-08-13 16:01","pubTimestamp":1755072089,"startTime":"0","endTime":"0","summary":"BMW is set to expand its capabilities with a new \"Center for Special and Individual Paints\" at its Dingolfing plant. The company is investing over 30 million euros to extend the existing vehicle paint shop, with construction beginning in September 2025 and production expected to start in spring 2027. The expansion will cover over 2,000 square meters and feature two work levels, allowing for a greater number of bespoke customer requests and special paint jobs to be processed more efficiently. Customers currently have the option to choose from up to 300 different paint colors, including unique two-tone designs and special coatings for limited editions such as the BMW 3.0 CSL and BMW M4 CS Edition VR46. The new facility is projected to employ a low double-digit number of staff, reducing processing time by roughly a quarter and lowering production costs. The drying process in the new area will utilize electricity rather than natural gas, aligning with energy-efficient practices. The facili","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLc7ysbM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7511","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2559606245","title":"How Investors May Respond To CSL (ASX:CSL) Gaining Canadian Approval for ANDEMBRY in Rare Disease Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2559606245","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559606245?lang=en_us&edition=fundamental","pubTime":"2025-08-13 14:45","pubTimestamp":1755067508,"startTime":"0","endTime":"0","summary":"CSL recently announced that Health Canada granted marketing authorization for ANDEMBRY (garadacimab), a monoclonal antibody for the routine prevention of hereditary angioedema attacks in patients aged 12 years and older.\nThis regulatory milestone gives CSL access to the Canadian HAE market with a product that showed very large reductions in attack frequency and sustained safety in pivotal studies.\nWe'll examine how ANDEMBRY's approval in Canada could strengthen CSL's position and growth...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-gaining-canadian-app","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0728928796.USD","ISBC","BK4086","CSL","SGXZ23171101.USD","BK4211","LU1169590202.USD","SG9999004303.SGD","BK7501","BK7511","LU1169589451.USD","CSL.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2559676252","title":"Should you buy the rebound in CSL shares today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2559676252","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559676252?lang=en_us&edition=fundamental","pubTime":"2025-08-13 11:48","pubTimestamp":1755056902,"startTime":"0","endTime":"0","summary":"CSL Ltd  shares are shaking off the broader selling action today and marching higher. Shares in the S&P/ASX 200 Index biotech stock closed yesterday trading for $264.31. At the time of writing on Wednesday afternoon, shares are changing hands for $269.41 apiece, up 1.9%. For some context, the ASX 200 is down 0.5% at this same time. With today's intraday gains factored in, CSL stock is now up more than 15% since the recent closing lows on 27 June. Over the past full year, however, CSL has underperformed the benchmark index, sinking 8.5% compared to the 12.9% one-year gain posted by the ASX 200. Though that performance doesn't include the  $4.25 in unfranked dividends CSL paid eligible stockholders over the full year. At the current price, CSL shares trade on an unfranked trailing dividend yield of 1.6%. Which brings us back to our headline question. CSL shares: Buy, hold, or sell?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/13/should-you-buy-the-rebound-in-csl-shares-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0728928796.USD","CSL.AU","BK7508","LU1169590202.USD","BK4086","LU1169589451.USD","CSL","BK7067","BK7511","BK7501","SGXZ23171101.USD","XJO.AU","SG9999004303.SGD"],"gpt_icon":0},{"id":"2559626215","title":"How to build a $250,000 ASX share portfolio starting at zero","url":"https://stock-news.laohu8.com/highlight/detail?id=2559626215","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559626215?lang=en_us&edition=fundamental","pubTime":"2025-08-13 02:33","pubTimestamp":1755023580,"startTime":"0","endTime":"0","summary":"Building a large share portfolio might sound like a big task, but with consistent investing and the power of compounding, it certainly is achievable. Let's walk through how you could grow a $250,000 A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/13/how-to-build-a-250000-asx-share-portfolio-starting-at-zero/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["NDQ.AU","PME.AU","BK7007","BK7094","RMD.AU","BK7501","IVV.AU"],"gpt_icon":0},{"id":"2558560623","title":"Beat the RBA cuts with these top ASX dividend stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2558560623","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558560623?lang=en_us&edition=fundamental","pubTime":"2025-08-12 22:11","pubTimestamp":1755007860,"startTime":"0","endTime":"0","summary":"Yesterday, the RBA elected to cut interest rates once again. While this is great news for borrowers, it is making life harder for income investors. But don't worry if you're in the latter group. That'","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/13/beat-the-rba-cuts-with-these-top-asx-dividend-stocks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7511","HDN.AU","BK7501","BK7062","BK7153","BK7162","BK7041","WES.AU","BK7005","PPT.AU","BK7040","EDV.AU","WOW.AU"],"gpt_icon":0},{"id":"2558964161","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2558964161","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558964161?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:32","pubTimestamp":1754998321,"startTime":"0","endTime":"0","summary":"WideOpenWest  shares were nearly 48% higher pre-bell Tuesday, a day after the company said it will be acquired by affiliated investment funds of DigitalBridge Investments and Crestview Partners in a $1.5 billion all-cash deal.Hanesbrands  stock was up 42% following a media report that Gildan Activewear  is closing in on a deal to acquire the company.180 Life Sciences  shares were 31% higher, extending gains from the previous session.FibroGen  stock was up about 22% after the company reported late Monday improved Q2 financial results.Sinclair  shares were 18% higher after the company said late Monday its board authorized a strategic review of its broadcast business.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7040","ATNF","BK4125","WOW.AU","BK4139","BK7511","BK4567","FGEN","GIL","BK4100","BK4202","HBI","BK7501","WOW","BK4505","BK4585","SBGI"],"gpt_icon":0},{"id":"2559624127","title":"Looking for big income? 2 ASX dividend stocks to buy today","url":"https://stock-news.laohu8.com/highlight/detail?id=2559624127","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559624127?lang=en_us&edition=fundamental","pubTime":"2025-08-12 13:33","pubTimestamp":1754976816,"startTime":"0","endTime":"0","summary":"With the S&P/ASX 200 Index (ASX: XJO) hitting a series of new all-time highs in 2025 so far (the latest just today), it's been a great time to be invested in ASX dividend stocks. However, while the ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/12/looking-for-big-income-2-asx-dividend-stocks-to-buy-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CBA.AU","BK7082","COL.AU","BK7042","BK7040","BK7511","BK7501","TLS.AU","BK7135","XJO.AU"],"gpt_icon":0},{"id":"2558314694","title":"BRIEF-Anteotech Executes Commission Agency Agreement With Kangshin Industrial Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2558314694","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558314694?lang=en_us&edition=fundamental","pubTime":"2025-08-12 09:31","pubTimestamp":1754962298,"startTime":"0","endTime":"0","summary":"BRIEF-Anteotech Executes Commission Agency Agreement With Kangshin Industrial CoAug 12 (Reuters) - Anteotech Ltd ADO.AX:APPOINTMENT OF SOUTH KOREAN DISTRIBUTOREXECUTES COMMISSION AGENCY AGREEMENT WITH KANGSHIN INDUSTRIAL COFurther company coverage: ADO.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUE70LPFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","BK7036","BK7501","ADO.AU","BK7508"],"gpt_icon":0},{"id":"2558696351","title":"Anteotech Ltd-Appointment of South Korean Distributor","url":"https://stock-news.laohu8.com/highlight/detail?id=2558696351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558696351?lang=en_us&edition=fundamental","pubTime":"2025-08-12 07:17","pubTimestamp":1754954249,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUE70LPFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7048","BK7036","ADO.AU"],"gpt_icon":0},{"id":"2558461923","title":"Here's Why We're Watching Starpharma Holdings' (ASX:SPL) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2558461923","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558461923?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:00","pubTimestamp":1754942450,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/heres-why-were-watching-starpharma-holdings-asxspl-cash-burn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SPL.AU","BK7096","BK7501","BK7508"],"gpt_icon":0},{"id":"2558763173","title":"Dimerix's Potential US FDA Approval Can Add AU$119 Million in Development Milestone Payments, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2558763173","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558763173?lang=en_us&edition=fundamental","pubTime":"2025-08-11 14:30","pubTimestamp":1754893854,"startTime":"0","endTime":"0","summary":"Dimerix's  potential successful interim readout could allow accelerated approval of DMX-200 in Focal Segmental Glomerulosclerosis, enabling US sales to start in the second half of calendar 2026, said Euroz Hartleys in a Monday note.The research firm noted that the company's US entry would significantly reduce its regulatory risk, as under its US licensing deal with Amicus Therapeutics, success might unlock up to AU$119 million in development milestone payments, equivalent to around AU$0.20 per share in cash.The research firm also noted that an additional AU$709 million could be earned in commercial milestone payments, and it would also receive tiered royalties in the low-teen to low-twenties percentage range based on US net sales.Euroz Hartleys has maintained its speculative buy recommendation with a price target of AU$1.68.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7067","DXB.AU","BK7508"],"gpt_icon":0},{"id":"2558319206","title":"Australian Regulator Proposes Granting Authorization to Establish Soft Plastic Recycling Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2558319206","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558319206?lang=en_us&edition=fundamental","pubTime":"2025-08-11 14:19","pubTimestamp":1754893196,"startTime":"0","endTime":"0","summary":"The Australian Competition and Consumer Commission issued a draft determination proposing to grant authorization to establish a voluntary, industry-led scheme to collect and recycle soft plastic packa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WOW.AU","NEX.SI","BK7040","BK7501","XKO.AU","COL.AU","BK6520","SES.SI","XJO.AU","BK7082","BK6039","XAO.AU","BK7511"],"gpt_icon":0},{"id":"2558687948","title":"CSL Shares Rise Upon Receipt of Canada Marketing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2558687948","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558687948?lang=en_us&edition=fundamental","pubTime":"2025-08-11 08:44","pubTimestamp":1754873054,"startTime":"0","endTime":"0","summary":"CSL  shares rose nearly 1% in morning trade Monday after the biotechnology company secured marketing authorization from Health Canada for Andembry as a once-monthly treatment for hereditary angioedema attacks in adult and pediatric patients aged 12 years and older.Andembry is designed to target activated FXII, a plasma protein that plays a key role in the attacks, according to the company's Friday, Aug. 8 release.Hereditary angioedema is a rare and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of swelling in various parts of the body.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999004303.SGD","BK7501","BK7508","CSL","BK7511","BK7067","SGXZ23171101.USD","LU0728928796.USD","CSL.AU","BK4086","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2558168052","title":"Noxopharm Advances HERACLES Trial as Sofra Platform Gains US Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2558168052","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558168052?lang=en_us&edition=fundamental","pubTime":"2025-08-11 08:42","pubTimestamp":1754872926,"startTime":"0","endTime":"0","summary":"Noxopharm  has successfully completed the second dosing cohort in its first-in-human HERACLES trial for novel autoimmune drug candidate SOF-SKN.The safety steering committee confirmed the dose level was safe and tolerable, enabling the study to progress to a higher concentration in the next cohort.The company also reported promising preclinical results from a US collaboration that could extend the reach of its Sofra technology into cancer and inflammatory disease markets.The HERACLES trial is evaluating SOF-SKN, a topical oligonucleotide-based therapy designed to treat autoimmune diseases such as cutaneous lupus erythematosus .Conducted in Australia, the study’s first phase involves four escalating single-dose cohorts, each with four participants.The stepwise design aims to minimise patient risk while identifying an optimal dose for later-stage trials.Each two-week cohort undergoes extensive testing and monitoring, with data reviewed by the safety steering committee before approval is ","market":"nz","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/08/Noxopharm-ASX-NOX-Advances-HERACLES-Trial-Sofra-Platform-US-Momentum.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/08/Noxopharm-ASX-NOX-Advances-HERACLES-Trial-Sofra-Platform-US-Momentum.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/noxopharm-advances-heracles-trial-sofra-platform-us-momentum/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["NOX.AU","BK7501","CLE.AU","BK7067","BK7095","BK7508"],"gpt_icon":0},{"id":"2558880682","title":"Noxopharm Ltd-Heracles Clinical Trial Update 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2558880682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558880682?lang=en_us&edition=fundamental","pubTime":"2025-08-11 06:31","pubTimestamp":1754865078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250810:nTUE3HBR5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","NOX.AU"],"gpt_icon":0},{"id":"2558468651","title":"2 ASX 200 shares that could make it rain dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2558468651","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558468651?lang=en_us&edition=fundamental","pubTime":"2025-08-11 04:30","pubTimestamp":1754857800,"startTime":"0","endTime":"0","summary":"S&P/ASX 200 Index (ASX: XJO) shares can be a great source of passive income because of their scale advantages. They generate enough profit to invest for growth and reward shareholders with dividends. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/11/2-asx-200-shares-that-could-make-it-rain-dividends-6/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WES.AU","BK7148","BK7511","APA.AU","XKO.AU","BK7153","BK7082","XAO.AU","BK7041","COL.AU","BK7040","BK7501","XJO.AU"],"gpt_icon":0},{"id":"2558683892","title":"Top brokers name 3 ASX shares to buy next week","url":"https://stock-news.laohu8.com/highlight/detail?id=2558683892","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558683892?lang=en_us&edition=fundamental","pubTime":"2025-08-10 05:19","pubTimestamp":1754774340,"startTime":"0","endTime":"0","summary":"It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Her","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/08/10/top-brokers-name-3-asx-shares-to-buy-next-week-10-august-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1720051017.SGD","LU1668664300.SGD","LU0912757837.SGD","BK4504","IE00BZ1G4Q59.USD","LU1732800096.USD","REA.AU","LU0098860793.USD","LU0158827781.USD","BK7503","LU0106261372.USD","BK4534","LU2028103732.USD","LU0106831901.USD","LU0234570918.USD","LU1162221912.USD","LU1732799900.SGD","LU1989772923.USD","LU2089284900.SGD","LU1989772840.SGD","LU0795875169.SGD","LU2357305700.SGD","LU1363072403.SGD","LU1548497426.USD","LU0267386448.USD","BK7501","LU2133065610.SGD","BK4516","IE00BKVL7J92.USD","BK7007","BK4581","LU1720051108.HKD","RMD.AU","LU0971096721.USD","LU2089283258.USD","LU2023251221.USD","LU0314104364.USD","LU0006306889.USD","LU0225283273.USD","BRG.AU","LU0795875086.SGD","BK4585","LU0158827948.USD","BK7002","LU0320765646.SGD","LU2271345857.HKD","BK4588","LU2347655156.SGD","LU1074936037.SGD","BK4127"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":73,"code":"91000000","status":"200"}]}}